Ra Pharmaceuticals Inc (RARX) Stock News

NASDAQ:RARX - Nasdaq -

47.995 -0.02 (-0.03%)

After market: 47.995 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RARX Latest News, Press Relases and Analysis

All

Press Releases

5 years ago - By: Seeking Alpha - Mentions: APLS ALXN BCRX AKTX ...

Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder (NASDAQ:APLS)

5 years ago - By: Zacks Investment Research

Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?

5 years ago - By: Zacks Investment Research

How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry

5 years ago - By: Benzinga - Mentions: OPK XBI ATHX HSIC ...

The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

5 years ago - By: Benzinga - Mentions: ASTC USAU

News Image

Stocks That Hit 52-Week Highs On Wednesday

5 years ago - By: StockNews.com - Mentions: VIR GH EBS BJ ...

News Image

Best & Worst Performing Mid Cap Stocks for March 12, 2020

5 years ago - By: Analyst Ratings - Mentions: ARNA

News Image

Analysts Offer Insights on Healthcare Companies: Ra Pharmaceuticals (NASDAQ: RARX) and Arena Pharma (NASDAQ: ARNA)

5 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

5 years ago - By: Seeking Alpha

Ra Pharmaceuticals EPS misses by $0.16

5 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

5 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

6 years ago - By: Zacks Investment Research - Mentions: ALKS INVA ANIK

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

6 years ago - By: Seeking Alpha

Ra Pharma commences mid-stage study of zilucoplan in rare type of myopathy

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

6 years ago - By: Halper Sadeh LLP - Mentions: IPHS FOMX

Merger Investigation Alert: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - IPHS, FOMX, RARX

6 years ago - By: Seeking Alpha

Ra Pharmaceuticals EPS misses by $0.05, beats on revenue

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

6 years ago - By: CNBC - Mentions: IBB AMGN CELG BIIB ...

Biotech stocks win October, rallying 8%